Clinical trial NCT04373720: MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
Official title: Pilot Study to Assess Mean Lesion Stiffness of Radiation Necrosis and Recurrent Glioma Using Magnetic Resonance Elastography (MRE) in Patients With Previously Treated Gliomas
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Glioma
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2020-05-04
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This trial uses magnetic resonance elastography (MRE) to estimate tissue stiffness (hardness or softness of the tissue) in tissue that is affected by radiation treatment (radiation necrosis) and tumor tissue that has come back (recurrent) after treatment in patients with gliomas. Diagnostic procedures, such as MRE, may estimate the differences in tissue stiffness between radiation necrosis and recurrent glioma post treatment and ultimately lead to a more accurate diagnosis and/or surgery, and/or a better assessment of the disease's response to treatment.

Detailed description: PRIMARY OBJECTIVES:

I. To estimate the mean lesion stiffness in patients with radiation necrosis using magnetic resonance elastography (MRE).

II. To estimate the mean lesion stiffness in patients with glioma recurrence using magnetic resonance elastography (MRE).

SECONDARY OBJECTIVE:

I. To investigate the mean lesion stiffness between radiation necrosis and glioma recurrence.

OUTLINE:

Patients undergo MRE over 10 minutes and then undergo standard of care magnetic resonance imaging (MRI) of the brain with and without contrast at baseline. Within 4 weeks after the initial MRI and MRE scans, patients may undergo standard of care biopsy to check the status of the disease. Within 48 hours after biopsy, patients undergo standard of care MRI to check the status of the disease. Patients who do not undergo biopsy undergo standard of care MRI 4-8 weeks after MRE scan to check the status of the disease.

Eligibility criteria: Inclusion Criteria

* \>/=18 years old.
* History of a pathology proven intracranial glioma (including IDH mutant, IDH wildtype or 1p19q co-deleted tumors) treated with chemotherapy and radiation.
* The lesion of concern (T2 Flair Hyperintense or contrast enhancing lesion) is \> 2 cm
* Patient is able to understand and give consent to participation in the study.

Exclusion Criteria

* Patients less than 18 years of age.
* Pregnant.
* Known allergy to gadolinium-based contrast agents.
* Renal failure as evidenced by a glomerular filtration rate (GFR) of less than 30 mL/min/1.73m2.
* Pacemakers, electronic stimulation, metallic foreign bodies and devices and/or other conditions that are not MR safe, which include but are not limited to:

  * electronically, magnetically, and mechanically activated implants
  * ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators and cardiac pacemakers
  * metallic splinters in the eye
  * ferromagnetic hemostatic clips in the central nervous system (CNS) or body
  * cochlear implants
  * other pacemakers, e.g., for the carotid sinus
  * insulin pumps and nerve stimulators
  * non-MR safe lead wires
  * prosthetic heart valves (if dehiscence is suspected)
  * non-ferromagnetic stapedial implants
  * claustrophobia that does not readily respond to oral medication

Primary outcomes:
measure: Mean lesion stiffness
timeFrame: At baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Melissa Chen, MD
role: PRINCIPAL_INVESTIGATOR
References: